The tobacco product landscape is evolving and the AACR Tobacco Products and Cancer Subcommittee has been cognizant of the shift from combusted products (e.g., cigarettes) to alternative nicotine delivery systems, such as e-cigarettes. While it is generally accepted that e-cigarettes are safer than traditional cigarettes, these products still present risks and the AACR has been active in trying to keep children from having access to them.Read More
Every month, the editors from the eight AACR journals select one “must read” article from each issue, which we highlight on this blog. For May, research articles span from an investigation of enzalutamide resistance in prostate cancer to an examination of how distance to care affects treatment initiation and completion among patients with cervical cancer living in urban and rural areas. As usual, all articles summarized here are freely available for a limited time.Read More
Shenzhen is a remarkable place. It serves as a gateway to Hong Kong, and in its short 40-year history has grown to become China’s seventh largest city, with a population of 20 million and some of Mainland China’s tallest buildings. The Fifth AACR New Horizons in Cancer Research (NHiCR) International Conference sessions have attracted more than 350 basic, clinical, and translational researchers and practitioners from throughout China, the Asia-Pacific region, and worldwide.Read More
Greetings from Shenzhen, China, where the Fifth AACR New Horizons in Cancer Research (NHiCR) Conference is now underway. The event’s aim is to create and further a global forum for the communication and exchange of knowledge and latest findings in basic, translational, and clinical research and to foster cooperation and network development, leading to a decrease in global cancer incidence and mortality. The conference is co-organized through the collaborative efforts of AACR, Peking University Shenzhen Graduate School, The State Key Laboratory of Chemical Oncogenomics, and Shenzhen Bay Laboratory.Read More
As a regular feature on this blog, we spotlight 10 “must read” articles selected by our editors from each journal issue published by the American Association for Cancer Research (AACR). For the month of April, articles span from a preclinical study of a selective HER-2 inhibitor to a report on the prevalence of cancer risk factors and screening rates in the United States. As always, all articles summarized here are freely available for a limited time.Read More
Therapeutics that target two proteins called cyclin-dependent kinase 4 (CDK4) and CDK6 have revolutionized treatment for breast cancer, Richard S. Finn, MD, told attendees of the Making Science Count for Patients: CDK4/6 special session during the recent AACR Annual Meeting 2019. This session was designed to review the progress made with this class of anticancer therapeutics, starting from basic science through preclinical and clinical development, and to look to what we might expect from these agents in the future.Read More
Over the course of AACR Annual Meeting 2019, there were 213 presentations on incredibly exciting clinical trials. This is a record number of clinical trial presentations for an AACR Annual Meeting. The trials presented covered the continuum of cancer treatment, from surgery, to radiotherapy and chemotherapy, to the two newest pillars of cancer care—molecularly targeted therapy and immunotherapy. The final clinical trials plenary session of the Annual Meeting epitomized this diversity by showcasing clinical trials reporting new ways to combine radiotherapy with other types of treatment, and new advances in immunotherapy and molecularly targeted therapy.Read More
About 80 percent of lung cancers are non-small cell lung cancers (NSCLC), and about 15 to 20 percent of NSCLCs harbor epidermal growth factor receptor (EGFR)-activating mutations.
Treatment for EGFR-mutant NSCLC improved dramatically with the introduction of EGFR tyrosine kinase inhibitors (TKIs). Several TKIs targeting this receptor have been developed, including the U.S. Food and Drug Administration (FDA)-approved first-generation EGFR TKIs gefitinib (Iressa) and erlotinib (Tarceva); second-generation EGFR TKIs, such as the FDA-approved afatinib (Gilotrif) and dacomitinib (Vizimpro), and the investigational therapeutic neratinib; and third-generation EGFR TKIs, including the FDA-approved osimertinib (Tagrisso), and the investigational therapeutics olmutinib and nazartinib.
The AACR-Bayer Innovation and Discovery Grants program supports researchers who are seeking to develop new treatment options for cancers with high unmet medical need. The program aims to encourage innovation and translation of ideas from basic research into novel drugs, and to foster collaborations between academic groups and the pharmaceutical industry.Read More
“Do you want to have fun?” Richard Pazdur, MD, director of the U.S. Food and Drug Administration (FDA) Oncology Center of Excellence, asked the audience as he opened the “PD-1 Pandemonium: FDA Speaks with Industry on the Past, Present, and Future of PD-1 Drugs” regulatory science and policy session at the American Association for Cancer Research (AACR) Annual Meeting 2019 on Monday, April 1.
Pazdur explained that he and AACR staff in the Science Policy and Government Affairs Office thought that it would be informative to convene representatives from all the companies who have an FDA-approved PD-1– or PD-L1–targeted immunotherapeutic for a heart-to-heart conversation about the past, present, and future of this group of revolutionary cancer treatments.Read More